Market news

Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. Presi

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial...

Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan.

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize...

Innovent Biologics, Inc. (01801.HK) and Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced an exclusive license agreement for IBI355 (Spero R&D code: SP001), a third-generation Fc-silent anti-CD40L antibody. Spero will receive exclusive rights to develop, research, manufacture, and commercialize IBI355 worldwide, excluding Greater China, where Innovent retains rights. Spero currently expects to advance IBI355 into a Phase 2 study in IgG4-RD patients in Q2 2027; Innovent expects to initiate

Spero Therapeutics, Inc. (NASDAQ:SPRO) has entered into a $105 million non-recourse, non-dilutive royalty financing agreement with affiliates of HealthCare Royalty (HCRx), a company majority owned by KKR & Co.